【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人。

Treatment of moderate-to severe vasomotor syndromes associated with menopause、hypoestrogenism due to castration.

Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principal intracellular human estrogen secreted prior to menopause.

Estradiol is well absorbed through GI tract and are widely distributed in the body (similar to endogenous estrogens). Estradiol is reversibly converted to estrone and estriol mainly in the liver. Estradiol is primarily excreted in the urine as metabolites estrone and estriol.

Hypersensitivity to estradiol or any component of the formulation; Breast cancer and endometrial cancer; Thromboembolic diseases (eg, stroke, MI, DVT, PE). Undiagnosed abnormal genital bleeding; estrogen-dependent tumor; hepatic dysfunction or disease; porphyria; pregnancy

X [FDA]

Enters breast milk/use caution

Nausea, vomiting, bloating, headache, weight gain, breast enlargement

Orally 1-2 mg/day, administration should be cyclic (3 weeks on, 1 week off) or daily. All dosage needs to be adjusted based upon the patient’s responses.